NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.26
$4.54
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume
576,770 shs
Average Volume
648,892 shs
Market Capitalization
$48.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TROV stock logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

TROV Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Cardiff Oncology (NASDAQ: CRDF)
Cardiff Oncology
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Cardiff Oncology: Staying The Course
Cardiff Oncology, Inc. (CRDF)
CRDF Cardiff Oncology, Inc.
Cardiff Oncology: Down But Not Out
See More Headlines
Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2020
Today
5/01/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-16,410,000.00
Net Margins
-3,688.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$0.94 per share

Miscellaneous

Free Float
N/A
Market Cap
$48.01 million
Optionable
Not Optionable
Beta
1.04
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mark Erlander
    Chief Executive Officer & Director
  • Vicki Kelemen
    Chief Operating Officer & Executive Vice President
  • Brigitte Lindsay
    Secretary & Vice President-Finance

TROV Stock Analysis - Frequently Asked Questions

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:TROV) released its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative trailing twelve-month return on equity of 202.00%.

When did Cardiff Oncology's stock split?

Cardiff Oncology's stock reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA).

This page (NASDAQ:TROV) was last updated on 5/1/2024 by MarketBeat.com Staff

From Our Partners